Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...

Summary: Insulin detemir is a long-acting, neutral, and soluble insulin analogue with a lower within-subject variability of fasting plasma glucose levels than isophane insulin human (NPH insulin ...

Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new ...

Novo Nordisk is discontinuing one of its discounted insulin brands, Levemir, because of manufacturing issues, decreasing patient coverage, and the availability of alternative treatments.

said the company's decision to discontinue Levemir, a long-acting insulin, "failed to take into ... was announced just before Novo Nordisk's 65% list price cut of Levemir took effect on January ...

In the meantime, Novo Nordisk has responded to the threat from the cut-price fast and long-acting insulins with newer insulins that aim to improve on the performance of the established rivals.